BridgeBio Pharma stock surged in premarket trading following U.S. regulatory approval for its treatment of transthyretin amyloid cardiomyopathy. The FDA approved Attruby for reducing cardiovascular risks. The company also submitted for approval in Europe with exclusive rights to Bayer for commercialization.